Angiostatin-Like Activity of a Monoclonal Antibody to the Catalytic Subunit of F1F0 ATP Synthase
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The antiangiogenic protein angiostatin inhibits ATP synthase on the endothelial cell surface, blocking cellular proliferation. To examine the specificity of this interaction, we generated monoclonal antibodies (mAb) directed against ATP synthase. mAb directed against the β-catalytic subunit of ATP synthase (MAb3D5AB1) inhibits the activity of the F1 domain of ATP synthase and recognizes the catalytic β-subunit of ATP synthase. We located the antibody recognition site of MAb3D5AB1 in domains containing the active site of the β-subunit. MAb3D5AB1 also binds to purified Escherichia coli F1 with an affinity 25-fold higher than the affinity of angiostatin for this protein. MAb3D5AB1 inhibits the hydrolytic activity of F1 ATP synthase at lower concentrations than angiostatin. Like angiostatin, MAb3D5AB1 inhibits ATP generation by ATP synthase on the endothelial cell surface in acidic conditions, the typical tumor microenvironment where cell surface ATP synthase exhibits greater activity. MAb3D5AB1 disrupts tube formation and decreases intracellular pH in endothelial cells exposed to low extracellular pH. Neither angiostatin nor MAb3D5AB1 showed an antiangiogenic effect in the corneal neovascularization assay; however, both were effective in the low-pH environment of the chicken chorioallantoic membrane assay. Thus, MAb3D5AB1 shows angiostatin-like properties superior to angiostatin and may be exploited in cancer chemotherapy. [Cancer Res 2007;67(10):4716–24]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Cited by
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
“Similarly, an antibody targeting the b catalytic subunit of F1F0 ATPase has an angiostatin-like antiangiogenic effect (Chi et al., 2007).”
BackgroundMitochondrial gateways to cancer
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 300
New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors
Corriden, R., & Insel, P. A. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9311-x · Cited by 78
Regenerative protein thymosin β-4 is a novel regulator of purinergic signaling.
Freeman, K. W., Bowman, B. R., & Zetter, B. R. (2011) · The FASEB Journal · doi:10.1096/fj.10-169417 · Cited by 72
Alard, J.-E., Hillion, S., Guillevin, L., Saraux, A., Pers, J.-O., Youinou, P., & Jamin, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014654 · Cited by 42
Metadata
- Authors
- Chi, S. L., Wahl, M. L., Mowery, Y. M., Shan, S., Mukhopadhyay, S., Hilderbrand, S. C., Kenan, D. J., Lipes, B. D., Johnson, C. E., Marusich, M. F., Capaldi, R. A., Dewhirst, M. W., & Pizzo, S. V.
- Venue
- Cancer Research
- Published
- 2007-05-15
- Volume
- 67
- Issue
- 10
- Pages
- 4716-4724
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2097199032
- Cited by
- 45
- References
- 1
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiostatin-Like Activity of a Monoclonal Antibody to the Catalytic Subunit of F1F0 ATP Synthase. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1094
- The paper
- Chi, S. L., Wahl, M. L., Mowery, Y. M., Shan, S., Mukhopadhyay, S., Hilderbrand, S. C., Kenan, D. J., Lipes, B. D., Johnson, C. E., Marusich, M. F., Capaldi, R. A., Dewhirst, M. W., & Pizzo, S. V. (2007). Angiostatin-Like Activity of a Monoclonal Antibody to the Catalytic Subunit of F1F0 ATP Synthase. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.